Reduced (±)-3,4-methylenedioxymethamphetamine (“Ecstasy”) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro

This publication has 25 references indexed in Scilit:

• Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humans
  British Journal of Clinical Pharmacology, 2000
• Acute Toxicity of 3,4-Methylenedioxymethamphetamine (MDMA) in Sprague–Dawley and Dark Agouti Rats
  Pharmacology Biochemistry and Behavior, 1999
• CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
  British Journal of Clinical Pharmacology, 1999
• Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, ?ecstasy?) and its congeners
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1997
• Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution
  Pharmacogenetics, 1997
• A novel mutant variant of the CYP2D6 gene (CYP2D617) common in a black African population: association with diminished debrisoquine hydroxylase activity
  British Journal of Clinical Pharmacology, 1996
• Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")
  The Lancet, 1992
• Simultaneous Determination of Dextromethorphan and Three Metabolites in Plasma and Urine Using High-Performance Liquid Chromatography with Application to Their Disposition in Man
  Therapeutic Drug Monitoring, 1990
• Identification of metabolites of 3,4-(methylenedioxy)methamphetamine in human urine
  Chemical Research in Toxicology, 1989
• POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
  The Lancet, 1977